Today, induced pluripotent stem cells (iPSCs) are being exploited for uses in drug discovery and development, toxicology screening, disease modelling, personalized medicine, cell-based therapeutics, and beyond. A fascinatingly diverse range of business models have been developed by market competitors to provide iPSC specific products, services, technologies, and therapies across the life science sector. [Read more…]
Is the CAR-T Cell Therapy Craze Driving Pharma Investment?
Without a doubt, the cell therapy industry is coming of age. In addition to growing numbers of cell therapy clinical trials, numerous cell therapy products have been approved by regulatory agencies worldwide and 150+ cell therapy companies are competing within the global marketplace. These metrics are extremely important because they indicate that the market for cell therapy products is expanding.
However, one of the most telling trends within the industry is a growing interest among Big Pharma in cell therapy companies. [Read more…]
Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Trial of AGLE-102™ in Patients with Dystrophic Epidermolysis Bullosa (“DEB”)
AGLE-102 is a novel extracellular vesicle therapy being developed for the treatment of rare and immuno-dermatological disorders.
WOBURN, Mass., Aug. 14, 2024 — Aegle Therapeutics Corp., a clinical-stage biopharmaceutical company developing novel extracellular vesicle (“EV”) therapies to address immune and inflammatory-based dermatological disorders, today announced that the first patient has been dosed in a Phase 1/2a clinical study evaluating AGLE-102™ for the treatment of the rare pediatric skin blistering disease DEB. [Read more…]
Setting the Standard in Adipose-Derived Stem Cell Applications
This article is part two of my interview with Matthew Feshbach, CEO and Co-Founder of Okyanos (pronounced “Oh – key – AH – nos”). Founded in 2011, Okyanos specializes in treating patients with chronic, degenerative conditions. Located in Freeport, Grand Bahama, just 55 miles from the United States, Okyanos Cell Therapy combines a blend of stem and regenerative cells derived from a patient’s own adipose (fat) tissue. [Read more…]
Nucleus Biologics Launches QuickStart Media™: A Suite of Optimized Media Formulations That Provide a Head Start on Your Therapy Optimization
SAN DIEGO, August 08, 2024 — Nucleus Biologics, The Cell Performance Company™, a leading provider of custom cell culture media and buffers for the cell and gene therapy industry, proudly announces the launch of a novel platform to expedite the formulation and manufacture of custom media. This platform, called QuickStart Media™, is a groundbreaking addition to its comprehensive line of cell culture products and solutions and further demonstrates Nucleus Biologics’ expertise and dedication to the delivery of custom cell culture media, buffers, reagents, and services simpler and faster. [Read more…]
- « Previous Page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- …
- 338
- Next Page »